The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS
· Delayed Price · Currency is USD
0.0010
0.00 (0.00%)
Apr 25, 2025, 2:36 PM EDT
GCAN Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
930.89K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 43.26M |
The Greater Cannabis Company News
- 4 months ago - GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing - GlobeNewsWire
- 1 year ago - GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire
- 1 year ago - GCANRx Featured in American Journal of Endocannabinoid Medicine - GlobeNewsWire
- 1 year ago - GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 2 years ago - GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 3 years ago - GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special - GlobeNewsWire
- 3 years ago - GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor - GlobeNewsWire
- 3 years ago - GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire